Clinical Trial Update: RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for RGX-121-3102 gene therapy in MPS II (Hunter syndrome) is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hunter Syndrome
• Mucopolysaccharidosis Type Ii

Drugs mentioned

• RGX-121-3102 (RGX-121-3102)

Snippet

Sponsor: REGENXBIO Inc. | Conditions: MPS II, Hunter Syndrome (MPS II) | Phase 3 | Status: ACTIVE_NOT_RECRUITING